Home' Australian Pharmacist : Australian Pharmacist June 2012 Contents 492 Australian Pharmacist June 2012 I ©Pharmaceutical Society of Australia Ltd.
Continuing Professional Development
The articles in this series are independently researched and compiled by PSA commissioned authors and peer reviewed.
Hyperhidrosis can cause social isolation
for the su erer and it is important that
these patients are treated appropriately
to ensure that isolation does not occur
and to minimise embarrassment in
It is essential that customers understand
the importance of taking their medication
as directed to get the greatest bene t
from their medication and to minimise
the risks associated with adverse e ects.
The pharmacist is in a position to
identify those patients who are at risk of
non-adherence and should continue to
monitor a patient's adherence, not just at
the initiation of therapy but throughout
the course of therapy.
1. Schwartz RA, Altman R, Kihiczak G. Hyperhidrosis. Medscape
[online] 2011 [accessed Feb 2012]. At: http://emedicine.
2. Smith CC, Pariser D. Primary focal hyperhidrosis. Up To Date
[online] 2011 [accessed Feb 2012]. At: www.uptodate.com/
3. Stolman LP. Treatment of hyperhidrosis. Dermatologic Clinics.
4. Homberger J, Grimes K, Naumann M, et al. Recognition,
diagnosis, and treatment of primary focal hyperhidrosis. J Am
Acad Dermatol. 2004; 51(2):274--86.
5. Therapeutic Guidelines: Hyperhidrosis [CD]. Melbourne:
Therapeutic Guidelines; 2011.
6. Hyperhidrosis. Clinical Evidence [online] 2011 [accessed Mar
2012]. At: http://bestpractice.bmj.com.ezproxy.utas.edu.au/
7. Collison DW. Bromohidrosis. Merck [online] 2007 [accessed
Apr 2012]. At: www.merckmanuals.com/professional/
8. Collison DW. Sweat glands. Merck [online] 2007 [accessed
Apr 2012]. At: www.merckmanuals.com/professional/
9. Causes of secondary hyperhidrosis. International Hyperhidrosis
Society [online] [accessed Apr 2012]. At: www.sweathelp.org/
10. Collison DW. Hyperhidrosis. Merck [online] 2008 [accessed
Mar 2012]. At: www.merckmanuals.com/professional/
11. Schnider P, Moraru E, Kittler H, et al. Treatment of focal
hyperhidrosis with botulinum toxin type A: long-term follow-
up in 61 patients. Br J Dermatol. 2001; 145(2):289--93.
12. Drott C, Gothberg G, Claes G. Endoscopic transthoracic
sympathectomy: an efficient and safe method for the
treatment of hyperhidrosis. J Am Acad Dermatol. 1995;
13. Eisenach JH, Atkinson JLD, Fealey RD. Hyperhidrosis. Evolving
therapies for a well-established phenomenon. Mayo Clin Proc.
1. Primary focal hyperhidrosis:
a) is associated with a family history of
b) usually begins in childhood or
c) has an easy to identify cause.
d) All of the above.
2. Which of the following is NOT
usually a ected by primary focal
3. Which of the following is NOT
a potential cause of secondary
a) Treatment with venlafaxine.
c) Parkinson's disease.
d) Drug withdrawal.
e) None of the above.
4. Which of the following would be
considered a rst line treatment for
a) An antiperspirant product containing
b) Formalin solution 2%.
c) An oral anticholinergic agent such as
d) Glutaraldehyde solution.
5. In regards to the use of Botox
in hyperhidrosis, which of the
following statements is TRUE?
a) Botox reduces or blocks neuronal
acetylcholine release from sympathetic
nerves innervating the eccrine glands.
b) Botox does not require the use of
anaesthetic when administered into
c) Botox is suitable only for hyperhidrosis
of the axillae.
d) There is no risk of muscle weakness
when Botox is used in the treatment of
A score of 4 out of 5 attracts 1.5 CPD credits.
Submit your answers online before
1 August 2012 at www.psa.org.au
and receive automatic feedback, or
PSA CPD answers
Pharmaceutical Society of Australia,
Level 1, 381 Royal Parade,
PARKVILLE VIC 3052
Fax: (03) 9389 4044
NZCP CPD answers,
PO Box 11 640,
Fax: (04) 381 4786
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of PSA's
CPD&PI program. It is also part of the New Zealand
College of Pharmacists (NZCP) education program
for NZ pharmacists.
The CPD section is recognised under the PSA
CPD&PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer. The credits allocated to
each section and the pass mark are shown with
CPD credits are allocated based on the length of
the article and the complexity of the information
presented. A minimum of 6 out of 8 questions, 4
out of 5 questions, or 3 out of 4 questions correct is
required for the allocation of Group 2 CPD Credits.
If not submitting online, write the correct answers
in the spaces provided on the answer panel on
the back of the address sheet, ll in your name,
member number and address details, then either
mail or fax the answer page to the relevant
address and fax number for marking.
PSA members can answer online at
www.psa.org.au and receive automatic feedback.
• You will need to login to submit your answers
online. If you do not have member access
details, you can request them via a link from
the login page.
• Select Pharmacist Members from the blue, left
hand side menu.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
Links Archive Australian Pharmacist July 2012 Australian Pharmacist May 2012 Navigation Previous Page Next Page